A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression
Sponsor: Ambrx, Inc.
A PHASE1 clinical study on Breast Neoplasms and Gastric Neoplasm, this trial is completed. The trial is conducted by Ambrx, Inc. and has accumulated 16 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 11 earlier versions
-
May 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
Dec 2022 — May 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2020 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ambrx, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .